Short answer: This article explains the key facts, eligibility issues, settlement factors, deadlines, and source-backed updates related to this legal topic. Results vary by case facts, evidence, jurisdiction, and representation.
The depo provera brain tumor lawsuit has become one of the largest pharmaceutical mass tort actions of 2026, with more than 3,700 women filing federal claims against Pfizer after developing meningioma — a type of intracranial brain tumor — following long-term use of the Depo-Provera contraceptive injection. If you or a loved one received Depo-Provera and were later diagnosed with a brain tumor, this guide explains eligibility criteria, estimated settlement ranges, filing deadlines, and what to expect from the litigation process.
At the center of the depo provera brain tumor lawsuit is a single, well-documented allegation: Pfizer knew — or should have known — that prolonged use of its injectable contraceptive significantly increases the risk of developing meningioma, yet failed to provide adequate warnings on product labels for years. A landmark 2023 study in the British Medical Journal confirmed a 5.6-fold increased meningioma risk for long-term Depo-Provera users, and the FDA updated its labeling accordingly in 2023 — facts that plaintiffs argue prove Pfizer’s pre-2023 warnings were dangerously inadequate.
| TortAdvisor Editorial Team
Free Depo-Provera Case Evaluation
Used Depo-Provera and diagnosed with meningioma? You may be eligible for significant compensation. Mass tort attorneys take these cases on contingency — zero upfront fees.
What Is the Depo Provera Brain Tumor Lawsuit?
This pharmaceutical litigation is a mass tort legal action against Pfizer, the manufacturer of Depo-Provera (medroxyprogesterone acetate, or MPA), brought by women who developed meningioma — a type of brain tumor — after receiving the injectable hormonal contraceptive for an extended period. Unlike isolated personal injury claims, the depo provera brain tumor lawsuit is consolidated into a federal Multi-District Litigation (MDL) proceeding: In re: Depo-Provera (Medroxyprogesterone Acetate) Products Liability Litigation, MDL No. 3140, in the Northern District of Florida before Judge M. Casey Rodgers.
Meningiomas develop on the protective membranes (meninges) surrounding the brain and spinal cord. While classified as “benign” in most cases, they can cause seizures, vision loss, severe headaches, cognitive impairment, and may require high-risk brain surgery — and they can recur. The severity of these injuries, combined with the volume of plaintiffs, makes this litigation one of the most consequential pharmaceutical liability actions currently active in U.S. federal court.
The core legal theory in these cases is failure to warn. Plaintiffs argue that Pfizer had access to European scientific data and regulatory warnings years before the FDA acted, but delayed updating U.S. labels — allowing thousands of women to be harmed while uninformed of the risk.
The Science: Depo-Provera and Meningioma Risk
The scientific evidence supporting the depo provera brain tumor lawsuit is strong and well-documented in peer-reviewed literature. Here is what the research shows:
2023 British Medical Journal Study: A large-scale epidemiological study using data from over one million women in France’s national health insurance database found that women who used Depo-Provera for more than one year had a 5.6-fold increased risk of developing intracranial meningioma compared to non-users. The study established a clear dose-response relationship — the longer the use, the greater the risk — which is exactly the kind of evidence plaintiffs need to prevail in the depo provera brain tumor lawsuit.
The Hormonal Mechanism: Depo-Provera works by releasing medroxyprogesterone acetate, a synthetic progestogen that suppresses ovulation. Meningioma tumor cells express high concentrations of progesterone receptors. MPA binds to these receptors and may stimulate tumor cell proliferation, providing a plausible biological mechanism for the association observed in epidemiological studies — a key element in establishing general causation in the depo provera brain tumor lawsuit.
European Regulatory Action: France’s national drug safety agency (ANSM) identified the meningioma risk associated with high-dose progestins and issued formal restrictions as early as 2019. The fact that European regulators acted nearly four years before the FDA took action in the U.S. is central to the failure-to-warn theory in this litigation.
2024 Confirmatory Studies: Additional peer-reviewed research published in 2024 across European patient populations confirmed the 2023 BMJ findings and strengthened the dose-response relationship between Depo-Provera duration and meningioma incidence — further solidifying the scientific foundation of these claims.
Depo-Provera Brain Tumor Lawsuit Settlement Amounts 2026
As of June 2026, no global settlement has been announced in the depo provera brain tumor lawsuit. However, based on comparable pharmaceutical mass tort precedents — including Roundup (glyphosate/NHL), Camp Lejeune, and NEC baby formula litigation — legal analysts have outlined projected settlement tiers:
| Severity Tier | Injury Profile | Estimated Range |
|---|---|---|
| Tier 1 — Severe | Brain surgery, permanent disability, recurrence, long-term care | $350,000 – $600,000+ |
| Tier 2 — Significant | Surgery required, extended recovery, some lasting neurological effects | $175,000 – $350,000 |
| Tier 3 — Moderate | Radiation/monitoring required, no surgery, limited lasting effects | $75,000 – $175,000 |
| Tier 4 — Baseline | Confirmed meningioma, watchful waiting protocol, documented Depo-Provera use | $25,000 – $75,000 |
These projections are not guarantees. Actual settlement values will depend on bellwether trial outcomes (expected 2027), the total number of qualifying claimants, Pfizer’s litigation strategy, and any new scientific or regulatory developments. Learn more about mass tort settlement calculations in our Settlement Amounts Hub.
Who Qualifies for the Depo Provera Brain Tumor Lawsuit?
Eligibility for the depo provera brain tumor lawsuit generally requires meeting all of the following criteria:
- Depo-Provera Use History: You received Depo-Provera (medroxyprogesterone acetate) injections for a minimum of 12 consecutive months. Longer usage history typically strengthens a claim and may support a higher settlement tier.
- Meningioma Diagnosis: You were diagnosed with meningioma, atypical meningioma, intracranial meningioma, or another progesterone receptor-positive intracranial tumor following your Depo-Provera use.
- Medical Documentation: You can provide pharmacy records, OB/GYN injection logs, or prescription history linking you to Depo-Provera; and MRI reports, pathology reports, or surgical records confirming your brain tumor diagnosis.
- Timely Filing: Your claim must be filed within your state’s statute of limitations — typically 2–3 years from diagnosis or from when you reasonably discovered the connection to Depo-Provera use.
Women who used Depo-Provera for less than 12 months, or who developed a non-meningioma brain tumor not linked to progesterone receptor activity, may face additional challenges qualifying for the depo provera brain tumor lawsuit, though each case is unique and should be evaluated by a qualified attorney.
Pfizer’s Liability and the Failure-to-Warn Theory
Pfizer’s liability in the depo provera brain tumor lawsuit centers on the learned intermediary doctrine and its duty to warn prescribing physicians of known or knowable risks. Key liability arguments include:
Delayed Label Update: European regulators flagged the meningioma risk from progestin therapies in 2019. The FDA did not update the Depo-Provera label until 2023 — four years later. Plaintiffs argue Pfizer should have proactively updated U.S. labels and communicated the risk to prescribing physicians long before the FDA required them to do so.
2023 FDA Label Change as Admission: When the FDA finally added a meningioma warning to the Depo-Provera label in 2023, it effectively confirmed that the prior warning was inadequate. For plaintiffs who used Depo-Provera before 2023 and were diagnosed with meningioma, this label change is powerful evidence supporting plaintiffs’ depo provera brain tumor lawsuit claims.
Pfizer’s Revenue vs. Risk: Depo-Provera generated hundreds of millions of dollars in annual revenue for Pfizer. Plaintiffs’ attorneys argue that the financial incentive to maintain broad prescribing without additional warnings contributed to Pfizer’s delayed response to the emerging meningioma data.
Discovery Proceedings: MDL discovery is now underway, and plaintiffs’ attorneys are seeking Pfizer internal communications, safety reports, and marketing materials dating back to the 1990s. In comparable pharmaceutical litigation, internal documents revealing corporate awareness of unreported risks have been pivotal in driving settlements.
How to File a Depo-Provera Brain Tumor Claim
Filing a claim in the depo provera brain tumor lawsuit follows a structured process. Here is what to expect:
Step 1 — Gather Medical Evidence
Collect all documentation of your Depo-Provera use (pharmacy records, OB/GYN visit records, vaccination/injection logs) and your meningioma diagnosis (MRI reports, pathology reports, surgical notes, radiation treatment records). The stronger your documentation, the stronger your potential recovery.
Step 2 — Contact a Mass Tort Attorney
Work with an attorney experienced in pharmaceutical mass tort litigation. All firms handling the depo provera brain tumor lawsuit operate on contingency — no fees unless your case resolves in your favor. Initial consultations are free with no obligation to proceed.
Step 3 — Case Evaluation and Filing
Your attorney will review your records, assess your eligibility, and determine your likely injury tier. If your case qualifies, they will file a Short Form Complaint in MDL No. 3140 in the Northern District of Florida, officially joining you to the consolidated litigation against Pfizer.
Step 4 — Discovery and Bellwether Trials
All MDL claimants benefit from shared common discovery. Bellwether trials scheduled for 2026–2027 will test key liability and damages arguments before juries, establishing the value range for all depo provera brain tumor lawsuit claimants.
Step 5 — Settlement or Trial
Most pharmaceutical MDLs resolve through global settlement after bellwether results provide guidance on case values. Your attorney will negotiate on your behalf and advise you on whether any settlement offer adequately compensates your injuries.
Statute of Limitations by State
Do not wait to file. The statute of limitations for the depo provera brain tumor lawsuit is a hard deadline — miss it and you may be permanently barred from recovery. Below are general limitations periods for product liability claims in key states:
| State | Limitations Period | Discovery Rule |
|---|---|---|
| California | 2 years | From date of discovery |
| Texas | 2 years | From injury or discovery |
| Florida | 2 years | From date of discovery |
| New York | 3 years | From date of discovery |
| Illinois | 2 years | From discovery of cause |
| Pennsylvania | 2 years | From diagnosis date |
| Ohio | 2 years | From discovery |
| Georgia | 2 years | From injury or discovery |
In many states, the “discovery rule” means your limitations period starts when you reasonably connect your meningioma diagnosis to your Depo-Provera use — not necessarily when you first received the injection. An attorney can evaluate your specific situation at no cost. View all active mass tort lawsuits to learn about other ongoing cases.
Depo Provera Brain Tumor Lawsuit Updates 2026: Latest MDL Milestones
The litigation is moving quickly. Here are the most key legal milestones as of mid-2026:
January 2026: The plaintiff count in MDL No. 3140 surpassed 3,700 individual claims — a 40% increase over the count reported in mid-2025. Attorney intake for new depo provera brain tumor cases continues at a high rate nationwide.
February 2026: Judge M. Casey Rodgers approved a pool of 100 cases for consideration as bellwether trial candidates. The court will narrow this pool to approximately 10–15 test cases that will proceed to trial beginning in early 2027.
March 2026: Expert witness designations were filed by both sides. Plaintiffs’ expert witnesses include neurologists, neuro-oncologists, pharmacologists, and FDA regulatory affairs specialists who will testify about causation, Pfizer’s knowledge timeline, and the adequacy of Depo-Provera’s pre-2023 labeling.
May 2026: Initial bellwether case selections were finalized. The first depo provera brain tumor lawsuit trials are expected to begin in the first quarter of 2027. Jury verdicts from these bellwether trials will heavily influence global settlement negotiations for all MDL claimants.
June 2026: The FDA announced plans for an advisory committee meeting in late 2026 to review the broader evidence linking synthetic progestins — including medroxyprogesterone acetate — to intracranial meningioma risk. Any additional regulatory action could significantly affect depo provera brain tumor lawsuit settlement dynamics.
Act Now — Deadlines Are Approaching
With bellwether trials beginning in 2027, the depo provera brain tumor lawsuit is entering a critical phase. Plaintiffs who delay may face statute of limitations issues. Call today for a free, confidential case evaluation — no upfront fees, ever.
Frequently Asked Questions — Depo Provera Brain Tumor Lawsuit
How many women have filed the depo provera brain tumor lawsuit?
As of June 2026, more than 3,700 women have filed depo provera brain tumor lawsuit claims in MDL No. 3140. The case count continues to grow as more women learn about the link between Depo-Provera and meningioma.
How long will it take to settle?
Most pharmaceutical MDLs take 3–7 years to fully resolve. Given that MDL No. 3140 was established in 2024 and bellwether trials begin in 2027, most depo provera brain tumor lawsuit claimants can expect resolution between 2027 and 2030.
Can I still file if I used Depo-Provera years ago?
Possibly. The discovery rule in many states allows the statute of limitations clock to start from when you connected your meningioma to Depo-Provera, not from when you received the injections. Speak with an attorney to evaluate your timeline.
Do I need surgery to qualify for the depo provera brain tumor lawsuit?
Not necessarily. Women whose meningioma required radiation or is under active monitoring may still qualify. However, surgical cases typically qualify for higher settlement tiers. A depo provera brain tumor lawsuit attorney can assess your specific situation.
What does it cost to file a depo provera brain tumor lawsuit claim?
Nothing upfront. Every attorney handling the depo provera brain tumor lawsuit works on contingency — they are paid only if and when your case resolves in your favor. Initial consultations are always free.
Sources & Citations
- Belbis M et al. “Meningioma and progestins.” British Medical Journal, 2023;382:e076923.
- FDA Drug Safety Communication: Depo-Provera Meningioma Risk Warning Update (2023).
- In re: Depo-Provera Products Liability Litigation, MDL No. 3140, N.D. Fla.
- National Cancer Institute. “Meningioma Treatment (PDQ).” 2024.
- Hage M et al. “Meningiomas and hormonal treatments: systematic review.” Neuro-Oncology Practice, 2024.
- ANSM France. Progestogens and meningioma risk: restriction recommendations. 2021.
- American Association of Neurological Surgeons. “Meningiomas.” AANS Patient Information.
- Harvard Health Publishing. “Depo-Provera and brain tumor risk.” 2024.
Related Posts
Discover what is SSI: eligibility, benefits, application process, SSI vs SSDI, and FAQs for low-income aged, blind, disabled.
Decades of scientific research, the IARC's 2024 Group 1 carcinogen reclassification, and J&J's failed bankruptcy attempts have reshaped the talcum powder lawsuit landscape in 2026. Learn what the science says, who qualifies, what settlements look like, and how to file a claim.
How to File a Snapchat Lawsuit 2026 If your child was sexually exploited, groomed, sextorted, or harmed on Snapchat, [...]
